(Q42963633)

11 November 2017

title

Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

11 November 2017

1 reference

1 reference

1 reference

1 reference

Catherine J Cone

1

1 reference

11 November 2017

Amy M Bachyrycz

series ordinal

2

1 reference

11 November 2017

Glen H Murata

series ordinal

3

1 reference

11 November 2017

language of work or name

English

0 references

publication date

31 August 2010

1 reference

Annals of Pharmacotherapy

11 November 2017

published in

1 reference

11 November 2017

volume

44

1 reference

11 November 2017

issue

10

1 reference

11 November 2017

page(s)

1655-1659

1 reference

Hepatotoxicity of drugs used for treatment of obesity and its comorbidities

11 November 2017

cites work

1 reference

21 January 2018

Metformin hepatotoxicity

1 reference

Metformin-induced acute hepatitis

21 January 2018

1 reference

Metformin-Induced Cholestatic Hepatitis

21 January 2018

1 reference

Possible metformin-induced hepatotoxicity

21 January 2018

1 reference

Cholestatic jaundice associated with the use of metformin

21 January 2018

1 reference

Nonalcoholic fatty liver disease: from steatosis to cirrhosis

21 January 2018

1 reference

Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists

21 January 2018

1 reference

Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries

21 January 2018

1 reference

AGA technical review on nonalcoholic fatty liver disease

21 January 2018

1 reference

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

21 January 2018

1 reference

Current treatment of non-alcoholic fatty liver disease.

21 January 2018

1 reference

Use of statins in patients with liver disease.

21 January 2018

1 reference

Drug-related hepatotoxicity

21 January 2018

1 reference

21 January 2018

The liver and lovastatin

1 reference

Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study

21 January 2018

1 reference

Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study

21 January 2018

1 reference

Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients.

21 January 2018

1 reference

Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project

21 January 2018

1 reference

Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia

21 January 2018

1 reference

Captopril-induced jaundice: report of 2 cases and a review of 13 additional reports in the literature

21 January 2018

1 reference

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1P099

1 reference

11 November 2017

1 reference